Oblato, Inc., has acquired all rights from OMRF to OKN-007, an investigational drug for the treatment of a deadly form of brain cancer.
deadly
Staying alive: Can an experimental OMRF drug stop Mike Schuster’s brain cancer?
As Mike Schuster nears the three-year anniversary of his diagnosis with glioblastoma, he’s already doubled the life expectancy for patients with the deadly cancer.
OMRF researcher tests new approach for treating deadly blood infection
Lupu’s findings were published in the Proceedings of the National Academy of Sciences.
